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Can positive behavioural support (PBS) assist STOMP medication challenge? 
Abstract 
Purpose: This study aims to investigate if Positive Behavioural Support (PBS) can 
be an effective alternative to medication, and can aid medication reduction in people 
with a learning disability, autism or both who are prescribed psychotropic medication 
for behaviour thought to be challenging. Background: STOMP is an initiative 
supported by NHS England which aims to reduce inappropriate prescribing of 
psychotropic medication, i.e. antipsychotics used for challenging behaviour in the 
absence of a documented mental health diagnosis. PBS has been described as the 
first line of intervention for behaviours which challenge (NICE, 2015) and has been 
highlighted as a non-pharmacological alternative to medication. Design: A two-
group, experimental design was utilised. Both groups were considered for 
medication reduction. The experimental group of 25 people received input from a 
specialist PBS team, while the control group of 29 people underwent unsupported 
medication challenge. Findings: There was a significantly higher success rate for 
medication reduction and discontinuation when PBS assessment and intervention 
was provided as an alternative to medication. Practical implications: This study 
indicates that providing PBS is associated with decreased medication and if 
replicated should be become standard practice for specialist teams. Further 
investigation into the specific components of PBS that aided medication reduction 
and discontinuation is required.  
Originality/Value: This is the first study to investigate the effect of PBS on 
medication reduction in patients prescribed psychotropic medication for behaviour 
thought to be challenging. 
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Stopping over-medication of people with a learning disability, autism or both 
(STOMP) is a project supported by NHS England aimed at reducing the 
inappropriate prescribing of psychotropic medication to manage behaviour that is 
deemed to be challenging in the absence of a documented mental health diagnosis 
(Branford et al 2018; NHS England 2016). The current project was launched in 2016 
following the report into the Winterbourne View care home which highlighted 
concerns related to the use of medication in this way (Department of Health 2012), in 
particular the off label and poorly evidenced use of psychotropic medication. 
Historically, little guidance has been available to guide the appropriate use of 
psychotropic medication (Tyrer et al., 2008; Deb et al., 2007, 2009).  
A report by Public Health England in 2015 (PHE, 2015) showed that 30,000-35,000 
prescriptions are issued each day to people with a learning disability and/or autism 
for psychotropic medication to manage behaviours, rather than as treatment for a 
serious mental illness. A UK population-based cohort study identified that people 
with a learning disability who presented with challenging behaviour were more than 
twice as likely to receive antipsychotic medication as those who did not have any 
behavioural challenge (Sheehan et al., 2015). 
In 2015 NICE (NICE, 2015) published a guidance document detailing how 
behaviours which challenge should be more appropriately managed placing the 
reliance on non-pharmacological methods as the first line intervention, with 
medication being considered only when other measures have not been successful in 
keeping the person safe. 
Behaviours which challenge is not a diagnostic criterion unlike serious mental illness. 
Diagnosis of serious mental illness is more difficult in people with a learning disability 
and there exists a potential for ambiguity between a presentation of serious mental 
illness and behaviours thought to be challenging which may lead to initiation of an 
inappropriate care pathway. 
These guidance documents demonstrate a shift in thinking away from reliance on 
medication and towards non-pharmacological interventions. Such interventions can 





people who historically have been in receipt of psychotropic medication without any 
specialist behavioural input. 
One non-pharmacological approach is the use of positive behavioural support (PBS), 
which is described in NICE guidance for individuals with behaviours which challenge 
(NICE, 2015). PBS is a framework to support understanding of the function of a 
person’s behaviour. It focuses on working collaboratively with the individual and 
people around them, including family members and other carers, to make changes to 
environments to better meet their needs. There is also an emphasis on teaching 
people new skills so they can communicate their needs in a different way. The 
overall aim of PBS is to improve the quality of life of the individual and those around 
them (Gore et al., 2013).  
There is little guidance for the ideal process of medication reduction and 
discontinuation. Much of the available literature highlights the success rate of 
medication reduction without any consideration of alternative intervention (Ahmed, 
2000; Branford, 1996; de Kuijper et al., 2014). In all these studies medication was 
reduced and removed without any other intervention being considered. Some studies 
have identified factors related to unsuccessful medication challenge which include 
environment, staff opinion, staff understanding of psychotropic medication and effect 
of physical ill health (Ramerman et al., 2018; de Kuijper et al., 2013, 2014; de Kuiper 
& Hoekstra, 2018). Many of these factors are considered within the PBS framework 
and intervention pathway described below.  
Given the historical reliance on medication, and the absence of any well-evidenced 
alternatives, we decided to explore the effectiveness of using PBS support to aid 
medication challenge for patients identified as suitable for a STOMP medication 
challenge. A control group was provided by a cohort of patients who had their 
medication challenged without the support of PBS practitioners. 
Aims 
• To investigate whether PBS can effectively support medication reduction 
• To assess the likely success of medication reduction with and without PBS 
involvement.  







A two-group experimental design was utilised. Both groups were considered for 
medication reduction. The experimental group received input from a specialist PBS 
team, while the control group underwent unsupported medication challenge. 
 
Participants 
In total, 54 patients took part in this study. 25 patients were in the experimental 
group and received PBS support alongside a medication challenge. 29 patients were 
in the control group and received unsupported medication challenge. Patient 
characteristics are shown in Table 2 but did not form part of the statistical analysis. 
[Table 1] Patient characteristics 
All patients were referred to the pharmacist independent prescriber for medication 
review. Referrals came through the PBS specialist, the PBS arm of the study or 
directly to the pharmacist from a General Practitioner or Care Team requesting a 
psychotropic medication review, the Non-PBS arm. The pharmacist allocated equal 
numbers to each arm of the study with four patients in the PBS arm being 
subsequently excluded due to changes in environmental factors prior to the work 
being initiated. Once each patient had been identified for a STOMP medication 
review they were referred to the pharmacist independent prescriber for challenge to 
medication. Patients in each arm of the study were required to meet the pharmacist’s 
inclusion criteria, shown in Table 2 based on the level of professional confidence and 
competence. 
[Table 2] Inclusion Criteria 
 
Procedure 
The PBS team and the pharmacist independent prescriber designed a PBS-STOMP 





the opinion and understanding of the patient and their care staff in relation to 
psychotropic medication and behavioural challenge. 
The pharmacist met with each patient and their care team, including paid and family 
carers, to discuss and potentially challenge the psychotropic prescription. Five 
patients received more than one psychotropic medication and it was agreed that one 
type would be challenged at a time rather than multiple challenges. Once agreement 
for challenge had been agreed by all parties the pharmacist began the medication 
challenge process following a similar design in both arms of the study.  
Table 3 shows the clinic process utilised by the pharmacist in all reviews with 
patients in both arms of the study. Both arms were collaborative, with key care staff 
and family members being invited to the review with the patient.  
In the PBS arm, behavioural data were collected by the care team and collated by 
the PBS practitioner. These data were presented at each PBS review to aid decision 
making in relation to medication in addition to the factors in Table 3.  
Within the PBS arm there was weekly support from the nurse practitioner in between 
the medication reviews. In the Non-PBS arm there was no support available between 
appointments. The PBS input continued beyond the end point of medication 
challenge for up to three months.  
[Table 3] Clinic Process 
Timescales and percentage dose changes were flexible and person-centred and not 
uniform in either arm of the study. As a minimum, the pharmacist agreed to meet the 
patient and people responsible for supporting their care approximately every 4-6 
weeks unless there were mitigating factors dictated by the care team such as 
changes to the patient’s environment.  
Following agreement to initiate the challenge to medication, the pharmacist 
continued with the reduction process, with the full agreement of each patient and 
their care team. Dose reductions were variable with the pharmacist setting the 
arbitary milestones of 25%. 50%, 75% of initial dosage to record specific 
achievements. These stages are detailed in Table 4 (the number of steps to achieve 





the patient and carers). 
[Table 4] Stages of medication reduction 
 
Materials 
In the PBS arm a variety of assessments and interventions were implemented based 
as needed after full functional behavioural assessment. The first stage of a PBS 
pathway includes functional assessment to ascertain the reason why a person may 
be behaving in a particular way. This is typically conducted by a Community Nurse 
with additional PBS training and/or experience. Other members of the Multi-
Disciplinary Team contribute to the assessment process, including support workers, 
speech and language therapists, occupational therapists and psychologists to 
ensure a holistic understanding of a person’s needs. Data from assessment were 
analysed and synthesised to help develop a working formulation of a person’s 
behaviour and the behaviour of those around them. A variety of interventions were 
used in the study based on functional understanding of an individual’s needs. 
Intervention packages typically offered to the PBS arm of the study included:  
1. The development of a Behaviour Support Plan (BSP). The purpose of a BSP 
is to provide a description of how an individual’s environment should be 
redesigned to reduce challenging behaviour and develop alternative 
behaviours (Chaplin et al., 2014). BSPs are aimed at direct carers and 
provide detailed instruction and prompt to guide carer behaviour.  
2. Carer training. Behaviours which challenge can be complex so it is often 
necessary to provide training or coaching to direct care staff and families 
(MacDonald & McGill, 2013). This training typically involves helping others 
understand challenging behaviour, as well as supporting people to understand 
and implement the BSP.  
3. Active support. This is an intervention that was designed to help staff working 
in small community homes for adults with Learning Disabilities (Totsika et al., 
2008). The approach equips staff to support meaningful engagement in 
activities and relationships by people with intellectual disabilities (Koritsas et 





The PBS practitioner(s) involved were responsible for conducting the 
assessment, and working collaboratively with a patient, their family and carers to 
negotiate and implement the most helpful interventions. The PBS practitioner 
also collected data to monitor the effectiveness of any interventions, and 
reformulate a patient’s needs when necessary. The data collected was used 
during the pharmacist’s review to open discussions with the patient and their 





Figure 1 describes the overall differences in STOMP challenge and medication 
reduction when supported by a PBS specialist compared to no such support (Non-
PBS). The number of patients were similar in each arm, with 25 in the PBS group 
and 29 in the non-PBS group. All were reviewed by the same pharmacist using 
similar referral criteria and review process. Within the PBS arm 130 reviews were 
carried out compared to 78 in the Non-PBS arm. Each PBS-supported patient 
attended a mean of 5.2 reviews compared to 2.7 without PBS. 
2) Initiation of medication reduction 
Of the 25 people supported by PBS 92% (n=23) agreed to initiation of medication 
challenge at the first pharmacist review. Without that support the initiation rate was 
41% (n=12) and many patients required multiple appointments before agreeing to 
medication challenge. This association between intervention and initiation was 
significant, χ2 = 15.09, p < .01. At the end of the study 15 people had still not agreed 
to medication challenge despite education and support from the pharmacist and PBS 
practitioner. Only one patient supported by PBS refused to initiate the medication 
challenge compared to 14 in the non-PBS arm. 





In the PBS arm, 15 (60%) patients successfully completed the discontinuation of 
medication compared to 15% without. A further 8 patients (32%) are actively 
undergoing STOMP medication challenge, in the PBS arm, without yet reaching an 
agreed final stage of challenge. The overall success rate for all patients in the study 
cannot yet be fully ascertained but could be between 60% and 92% of participants.  
 
Restarting or increasing medication 
In the PBS arm, one patient needed medication to be reintroduced or increased 
following discontinuation or reduction compared to eight patients in the non-PBS 
arm. The one PBS patient who needed medication to be restarted following 
successful discontinuation was due to a perceived increase in behavioural challenge 
and no PBS supported patients needed a medication increase following a reduction.  
. There was a significant association between the use of PBS and prescribing, χ2 = 
16.6124, p < .01. Inspection of the frequencies reveals that PBS was associated with 
significantly more patients having their medication stopped, while non-PBS patients 
were more likely to have their medication increased following an initial reduction  
Type of medication Challenge 
 
[Figure 2] 
Figure 2 shows the type of medication that was challenged throughout the process. 
All were antipsychotics thereby gaining continuity of prescription type. More than half 
of the prescriptions were for risperidone (52%). All other antipsychotics were atypical 
in nature with no patients being referred to the clinic on a typical type of medication. 
It was not the intention of this study to look at specific medications.  
 
Discussion 
This study set out to ascertain whether PBS supported the success of STOMP 






In the literature review, most historical studies had focused on medication reduction 
unsupported by other interventions. The most recent published work, by de Kuijper 
et al. (2014), the successful discontinuation rate was 61% two weeks after stopping 
medication falling to 46% three months later. The PBS group demonstrated a similar 
discontinuation rate to that found by de Kuijper (61% de Kuijper vs. 60% in this 
study) although a further 32% of patients are still undergoing medication reduction 
and this success rate may considerable increase. A difference to the Dutch study is 
that after three months of discontinuation the success rate with PBS support had 
reduced slightly to 56%. This is a smaller decrease compared to the Dutch research 
(56%:46%) This improvement compared to recent studies points to a measurable 
impact of PBS support 
The data show a difference in medication challenge medication when supported by 
PBS methods and when not. At each stage of the process, initiating a reduction 
schedule there is a difference between the two groups, pointing to greater success 
with the support of PBS. 
1. Initiation of a reduction schedule 
Patients and their care team were far more likely to agree to medication challenge 
when supported by the PBS practitioner than when unsupported. The reasons 
underpinning the difference in likelihood to initiate a reduction schedule between the 
two arms of the study may be multifactorial but points to the role of PBS in 
challenging and exploring the concerns to medication challenge through education 
and support. The full behavioural assessment may also help support teams and 
family members to better understand their patient’s needs before initiating reduction. 
This may lead to more effective management strategies being implemented as well 
as a better understanding of behavioural function and the ruling out of physical 
causes and environmental factors.  
The PBS pathway highlights STOMP education at the point of initial assessment and 
the theme develops throughout the work of the team. The focus enabled discussion 
in the early stage of contact and the skilled practitioner would then decide the point 
of referral for a STOMP medication challenge having completed the educational 
element of the work. This could have contributed to the majority of patients agreeing 





excluded much of the background and educational awareness and could focus on 
the medication challenge process and measures of success and concern. 
In the Non-PBS arm the patient and their support staff were educated about STOMP 
at their first appointment. In all cases they had no awareness about STOMP and 
mentioning medication challenge drove significant concern in both the patient and 
their care team. Where medication challenge was considered it was with a specific 
reason such as side effect burden or concern in relation to long term medication 
usage. The issue of STOMP awareness and education relating to medication risks 
and benefits could be seen to play a part in the success of medication challenge. 
2. Subsequent reductions 
The data demonstrates that more patients continued with the reduction process 
when supported by PBS practitioners. In 70% of reviews, with PBS support, the 
reduction schedule continued as planned with a further reduction being initiated at 
subsequent appointments. In the remaining cases the reduction was delayed by 
other factors such as seasonal variations in presentation, changes in staff or physical 
ill health requiring intervention such as pain, infection or poor bowel management 
plans. This often delayed but did not stop the process. No patient had to be excluded 
due to significant physical ill health or worsening of mental wellbeing. These would 
have been immediate exclusion criteria for this study. There is always a risk that 
medication challenge, especially of an antipsychotic, may unmask a previously 
undiagnosed serious mental illness. 
In the Non-PBS group many patients believed that the initial reduction was also the 
final one and that STOMP reviews stopped with this initial reduction. It became 
difficult to shift this thinking in the care team who displayed the same initial anxiety 
about reduction as when it was first discussed. The educational input and ongoing 
support from the PBS practitioner could have contributed to patient and carers 
agreeing to additional medication challenge. At each review the PBS practitioner 
discussed the data collected in relation to the behavioural challenge which the 
pharmacist used to drive prescribing decisions. A pictorial representation of 
behavioural data, often in graph format, demonstrated the impact of medication 
challenge as well as other interventions made by the PBS practitioner. This allowed 





reduction and a greater understanding of the function of behaviour i.e. meeting a 
patient’s need. For example, in one case of successful medication challenge, the 
frequency of behaviours increased as the severity diminished. In this case staff 
understood that the function of the behaviour was communicative in nature and they 
responded differently to meet an unmet need. This understanding enabled the 
medication challenge to continue with renewed confidence from the team. 
3. Medication discontinuation 
The number of patients progressing to full discontinuation was also more evident in 
the PBS-supported group. The use of behavioural data at each stage of the process 
allowed for a clear understanding of impact of medication reduction together with 
non-pharmacological input to support each individual. The progress to 
discontinuation was smoother, less likely to involve a change in reduction rate and 
more likely to succeed. In most of the successful cases of discontinuation the PBS 
practitioner would remain involved with the team on a weekly basis, being there to 
provide reassurance, support and a functional understanding of behaviour. Each 
prescribing decision within the PBS arm was driven by behavioural data recorded by 
the staff team and collated by the PBS practitioner. This data could collection 
continued beyond discontinuation to provide a degree of reassurance as the patient 
acclimatised to being medication free. This continued for at least three months after 
discontinuation which could prove invaluable to the patient and their care teams. It 
was evident that prior to initiation and at the point of discontinuation were the times 
of greatest concern about the process. Having a trusted support practitioner to 
oversee both these critical points in the process could have contributed to more 
successful outcomes. During this time frame only one patient required medication to 
be restarted which reduced the overall discontinuation rate from 60% to 56%. This 
compares the reduction in discontinuation rate of 61% to 46% in de Kuijper et al.’s 
(2014) study. This therefore indicates that use of PBS is associated with better 
medium term outcomes in relation to medication discontinuation. Further work 
should explore the outcomes over a longer period of time to determine whether the 
reductions/discontinuation of medication is maintained. 
4. Medication restarting or dose increased 





supported by PBS. The team remained as support for the care staff for a minimum of 
three months post discontinuation or cessation of the medication challenge. This 
compared to 66% when not supported by PBS. This element of continuing support 
and focus on behavioural intervention could have allowed successful medication 
challenge to be maintained and to support care teams to focus on continuing non-
pharmacological intervention well beyond medication discontinuation. 
Limitations and future research 
Although the data presented in this study indicate that PBS involvement may support 
medication reduction, it is unclear which specific components of the framework are 
helpful. While it appears that a functional understanding of behaviour, and an 
alternative intervention means that medication reduction is likely to be more 
successful than the unsupported model, this study alone is unable to draw those 
conclusions. One could hypothesise that PBS input means that families and staff feel 
supported to look at alternatives, and are provided with awareness and education 
regarding a functional understanding of behaviour. Full consideration of staff 
attitudes and concerns, together with an environmental assessment and the 
exclusion of physical ill-health factors, may lead to increased chances of successful 
medication challenge. Further research is needed to understand what specific 
elements or interventions have the greatest significance on successful medication 
challenge. 
This study did not set out to measure quality of life improvements linked to 
successful medication challenge as it was beyond the scope of this paper. 
Although we believe that our results are robust, a larger sample would have helped 
strengthen our claims. A sample size calculation indicated a sample of 105 would 
have been sufficient (with a confidence level of 95% and a margin of error of 5%). 
Future studies should therefore aim to recruit a larger participant group and make 
greater use of statistical techniques to explore differences between the two arms of 
the study. 
The work does not capture how much input was given to each person before the 
pharmacist began to reduce medication. Similarly, it does not capture the type of 





work will be needed to consider the impact of specific interventions and type of 
support. Similarly, it would be beneficial to capture the type of staff and carer 
concerns that PBS specialists are able to overcome prior to prescriber involvement. 
Conclusion and Clinical Implications 
This study indicates that PBS support could enable more robust medication 
challenge from initiation through each stage of reduction to successful 
discontinuation and medication-free maintenance. It is possible that PBS support 
could overcome patient and staff reluctance through education, assessment and 
functional understanding of behaviour and management of environmental and 
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Table 1. Inclusion referral criteria to the PBS-STOM1Anti-epileptics being used for mood  
  
REFERRAL CRITERIA  
• Stable behaviours No worsening of baseline frequency, severity 
and duration if data available 
  
• Stable physical health Well managed physical health without 
significant physical health co-morbidity 
  
• Stable epilepsy No more than TWO anti-epileptics and well 
controlled seizure activity 
 
• No mental health diagnosis Historical or current 
 
• Psychotropic medication Antipsychotics, antidepressants, mood 
stabilisers1, anxiolytics and hypnotics 
excluding anti-epileptics just for epilepsy 





Table 2. The pharmacist process for all reviews PBS and Non-PBS 














































sleep and dietary 
charts 
 
Benefits in relation 
to target 
behaviours 
Side effect burden 






General information, background, 
aims 
 
Expectations and concerns of 
medication challenge 
 





Key factor stability and optimal 





Data-driven decision making 
 
Grading system to quantify changes 
 
 








Table 3. Stages of medication challenge with the requirements for success 
STAGE                 REQUIREMENTS 
  
INITIATION Agreement to start a medication reduction programme on first 
meeting with the pharmacist 
  
REDUCTION STAGES 25%                 Maintained for at least 4 weeks to  





Full removal of the medication for at least 4 weeks 
RESTART or INCREASE A dose increase or medication being restarted after 4 weeks or 





























































Risperidone Quetiapine Olanzapine Aripiprazole Amisulpride
